N/A N=10 rTMS Therapy for Primary Orthostatic Tremor
Primary Orthostatic Tremor
Primary: Change in Fullerton Advanced Balance (FAB) Scale Total Score After rTMS — 2.8; 0.9 change in score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=9 Lundbeck TOMs Orthostatic Hypotension
Orthostatic Hypotension · Idiopathic Parkinson Disease
Primary: Orthostatic Hypotension Questionnaire (OHQ) Score — 4.6 score on a scale
Phase 4 N=56 Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response
Essential Tremor · Tremor
Primary: Regions With fMRI Differences Between ET and Controls — 139; 93; 85; 74 Number of Activated Voxels
Phase 2 N=19 Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor
Essential Tremor
Primary: Normalized Accelerometric Tremor Power, Dominant Hand, 80min After Administration, Weighted Condition — 0.669; 0.798 ratio — p==0.345
N/A N=356 Orthostatic Hypotension Treatment on Rehab Unit
Orthostatic Hypotension · Falls
Primary: Orthostatic Hypotension at Discharge — 39; 44 Participants — p=0.6
Phase 4 N=18 Propranolol and Botulinum Toxin for Essential Vocal Tremor
Essential Vocal Tremor · Essential Voice Tremor · Essential Tremor
Primary: Change in Quality of Life in Essential Tremor (QUEST) Questionnaire Score — 39.41; 29.50; 23.60 units on a scale
Early Phase 1 N=20 Pregabalin in the Treatment of Essential Tremor
Essential Tremor
Primary: Change in Tremor Rating Scale (TRS) Compared With Baseline. — 2.4; -0.2; 6.7; 3.6 units on a scale
Phase 2 N=11 Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor
Essential Tremor
Primary: Normalized Mean Tremor Amplitude for Both Formulations of 64 mg/kg 1-Octanol in Part B — 1; 1; 1.009; 0.901 normalized score on a scale
Phase 4 N=87 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
Orthostatic; Hypotension, Neurogenic
Primary: Change in Orthostatic BP Drop — 11.1; 13.6; 8.9; 7.5 mmHg
Phase 3 N=26 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Change in Heart Rate — 17.0; 13.1 beats per minute
N/A N=341 Orthostatic Hypotension in Rehabilitation Patients
Hypotension, Orthostatic
Primary: Orthostatic Hypotension at Discharge — 96 participants
Phase 3 N=40 Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
Parkinson Disease · Orthostatic Hypotension
Primary: Change in Systolic Blood Pressure From Supine to Tilt at 3 Minutes — -24.22; -20.32 mmHg
Phase 3 N=181 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1) — 1.3; 1.9 units on a scale — p=0.509
Phase 2 N=109 Sex Hormones and Orthostatic Tolerance
Orthostatic Intolerance
Primary: Orthostatic Tolerance — 634 mmHg*min
Phase 2 N=17 Effects of Octanoic Acid for Treatment of Essential Voice Tremor
Essential Voice Tremor · Vocal Tremor · Voice Tremor
Primary: Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor — 12.91; 13.49; 12.43; 9.35 percentage of voice signal with tremor — p=0.0216
Phase 3 N=263 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Orthostatic Hypotension Questionnaire Score (OHQ) — -1.83; -0.93 units on a scale — p=0.003
N/A N=1,699 Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life
Parkinson Disease
Primary: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at the End of Maintenance — 5.20 Points on UPDRS scale
N/A N=20 Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor
Tremor
Primary: Tremor Amplitude — 127; 104; 150; 100 cm/s^2
N/A N=12 Effect of Exercise in OI
Orthostatic Intolerance · Postural Tachycardia Syndrome
Primary: Maximal Oxygen Consumption Capacity (VO2 Max) — 27.6; 24.5 mL/kg/min
Phase 4 N=140 A Study for Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale — 4.1; 5.2 scores on a scale — p=<0.001
Phase 2 N=15 Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD)
Parkinson's Disease · Neurogenic Orthostatic Hypotension in Parkinson's Disease
Primary: Change in Mean Blood Pressure (mmHg) After 3 Minutes of Passive Orthostatic Challenge From Baseline, When Wearing an Elastic Abdominal Binder vs a Placebo Binder for 2…
Phase 4 N=453 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Symptomatic Neurogenic Orthostatic Hypotension
Primary: Time To Intervention — 52.00; 42.00; NA; NA Days — p=0.803
Phase 4 N=98 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Symptomatic Orthostatic Hypotension
Primary: Percent of Subjects Who Failed to Maintain a Response — 30.3; 44.1 percentage of participants — p=0.3145
Phase 2 N=6 Intravenous Norepinephrine for Orthostatic Hypotension
Orthostatic Hypertension
Primary: Blood Pressure (Systolic) — 156; 158; 179; 148 mm Hg
Phase 3 N=103 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
Neurogenic Orthostatic Hypotension · Non-Diabetic Autonomic Neuropathy · Multiple System Atrophy
Primary: Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ) — 0.57; 0.90 units on a scale — p=0.438
N/A N=12 Repetitive Transcranial Magnetic Stimulation (rTMS) for Dystonia and Tremor
Dystonia · Tremor
Primary: Cognitive Assessment Using MoCA Version 7.1 Scores — 25.45; 27 units on a scale
Phase 2 N=16 Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease
Parkinson Disease
Primary: Change in the MDS-UPDRS Tremor Subscore — 0.25; 0.27 score on a scale — p=0.5
Phase 4 N=100 Overactive Bladder Innovative Therapy Trial (OrBIT)
Overactive Bladder
Primary: Frequency of Voids at 12 Weeks — -2.4; -2.5 Voids/day
Phase 4 N=24 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
Orthostatic Hypotension
Primary: Time to Onset of Syncope/Near Syncope While on Tilt Table — 1105.6; 1626.6 seconds — p=0.0131
Phase 2 N=25 A Clinical Study to Evaluate CAD-1883 in Essential Tremor
Essential Tremor
Primary: Evaluate the Occurrence and Severity of Treatment Emergent AEs. — 13; 9; 2; 2 participants